Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

By J. Wess, R. Eglen, D. Gautam. 2007

625 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

In Molecular Biology

Citations in the corpus

Ligand biological activity predicted by cleaning positive and negative chemical correlations (2019, background): “Gene knockout studies suggest that the M1 agonists may ameliorate the symptoms of Alzheimer’s disease and related cognitive disorders as well as ameliorate psychosis-like symptoms in schizophrenia (37, 38).”
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders (2009, background): “Muscarinic acetylcholine receptors (mAChRs) are a family of five receptors (classed M1–M5) that are involved in a wide variety of biological processes and disease states, including pain, Alzheimer's disease, schizophrenia, diabetes and obesit”
The effect of pain on cognitive function: a review of clinical and preclinical research. (2011, background): “Muscarinic receptor agonists, such as vendacycline, oxotremorine, CMI-936 and CMI-1145, have also shown potent analgesic action (Tata, 2008; Wess et al., 2007).”
Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor (2012, background): “Unfortunately, despite decades of effort, no therapeutic agents endowed with clear mAChR subtype selectivity have been developed to exploit these difference”
Modifications to five-substituted 3,3-diethyl-4,5-dihydro-2(3H)-furanones en route to novel muscarinic receptor ligands (2011, background): “been targeted in drug discovery efforts for the treatment of various disorders including overactive bladder, Alzheimer’s disease, pain, cognitive impairment, drug addiction, schizophrenia, and parkinson’s disease (Abrams et al., 2006; Wess et al., 2007).”
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist (2012, background): “As a consequence of their roles in both the central and parasympathetic nervous systems, muscarinic receptors are targets for the treatment of a spectrum of disorders including Alzheimer’s disease, schizophrenia and Parkinson’s disease, and chronic obstructive pulmonary diseas”